Defining the therapeutic potential of host-targeted approaches for combating COVID-19 (Shirit Einav)

Einav’s lab is researching repurposed and novel anti-viral approaches targeting two cellular kinases that are an Achilles’ heel of multiple unrelated RNA viruses. Their data show that a combination of two already-approved anti-cancer drugs that act against these kinases inhibits replication of multiple viruses in vitro and reduces mortality in mice infected with the dengue or Ebola viruses. The lab has also been developing more selective compounds that target these cellular kinases and have potent activity against multiple RNA viruses, including flaviviruses and coronaviruses, both in vitro and in human primary cells. Stanford Office of Technology Licensing 650-723-0651

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More